AI Can Detect Lung Nodules that Could Lead to Lung Cancer Nearly 3 Years Before Symptoms & Actual Diagnosis | Study finds

The evidence presented at 2024 World Conference on Lung Cancer highlights chest X-ray AI’s potential to detect lung nodules early and expedite patient care

AI Can Detect Lung Nodules: A new study has been unveiled at the International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on Lung Cancerin San Diego, CA citing promising initial results using AI-powered chest X-ray interpretation to detect pulmonary nodules which could develop into early-stage lung cancers long before symptoms appear. The retrospective study demonstrated via interim results, an average diagnostic delay of nearly three years from the first abnormal chest X-ray.

The study conducted at the Phrapokklao Hospital’s Cancer Centre of Excellence in Bangkok, Thailand was led by Dr Passakorn Wanchaijiraboon, Medical Oncologist and Deputy Director using the Qure.ai chest X-ray AI solution qXR.

Dr. Passakorn Wanchaijiraboon, while unveiling the poster, said;

“This abstract study, presented at the World Conference on Lung Cancer, provides a snapshot of the significant potential that AI-assisted chest X-ray analysis holds for transforming early cancer detection and reducing the rate of missed lung cancer diagnoses. In most Thai government hospitals, chest X-rays are interpreted by non-radiologists. However, in community hospitals, there are often no radiologists available to read chest X-rays at all. By overlaying specialist AI to read all cases, we can support clinicians in detecting incidental high-risk nodules that may lead to lung cancer. This approach can streamline decision-making and potentially improve patient survival through the earlier diagnosis of cancer. The implementation of CXR AI is particularly beneficial in the context of community hospitals, where it can significantly enhance diagnostic capabilities in the absence of on-site radiologists.” 

The Phrapokklao Cancer Centre study retrospectively reviewed and evaluated the chest X-ray image database of newly diagnosed lung cancer patients over an annual period using qXR. Missed lung cancer was defined as missed in the original report six months prior to a definitive lung cancer diagnosis. 18% of patient cases were found to have a missed lung cancer diagnosis over an average period of nearly three years (32.3 months), with a maximum duration of over eight years (96 months) and minimum eight months. Half the patient cases had chest X-rays taken for non-respiratory symptoms as part of a health check-up, categorising them as ‘incidentally detected’.

Bhargava Reddy, Chief Business Officer, Oncology at Qure.ai

“This is an exciting evidence example that underscores the transformative potential of AI in the fight against lung cancer. Overlaying AI on chest X-rays casts the net wider by proactively triaging patients for the risk of lung cancer. It goes beyond people with symptoms or qualifying for screening initiatives based on age or smoking history, to currently invisible and unprofiled patient populations thus detecting lung cancers earlier.”

Lung Cancer has one of the poorest survival outcomes of all cancers, with over two-thirds of patients diagnosed at an advanced stage, when curative treatment is no longer feasible1. Missed lung cancer is a source of concern for clinicians and an important medicolegal challenge2. Missed nodules resulting from lung cancer are the third most common reason for malpractice claims 3.

IASLC 2024 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer (#WCLC24) is being held September 7 to 10 in San Diego, California. The Phrapokklao Cancer Centre study poster abstract presented can be viewed here: https://www.qure.ai/evidence/The-potential-of-chest-X-ray-Al-in-detecting-missed-lung-cancer-diagnosis-in-a-community-based-cancer-center-in-thailand

AI can detect lung nodules news
A case of maximum missed lung cancer nodules, diagnosis duration of 97 months
1st image: Prior Chest X ray; 2nd Image: AI result; 3rd Image: Chest X ray at diagnosis
CT image at diagnosis
Chest X ray of patient with nodule detected by AI/qXR 23 months prior to the diagnosis of lung cancer. The X-ray was obtained as a part of health check-up.

References

1,2 – https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338577/

3 – https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431813/

 

SourceQure.ai

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version